Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBT (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of EBT data on record, last reported at -$5.0 million in Q4 2025.

  • For Q4 2025, EBT rose 79.63% year-over-year to -$5.0 million; the TTM value through Dec 2025 reached -$21.4 million, up 75.35%, while the annual FY2025 figure was -$21.4 million, 75.35% up from the prior year.
  • EBT reached -$5.0 million in Q4 2025 per MIRM's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, EBT topped out at $57.3 million in Q4 2021 and bottomed at -$73.7 million in Q2 2023.
  • Average EBT over 5 years is -$24.9 million, with a median of -$27.3 million recorded in 2023.
  • Peak YoY movement for EBT: soared 254.01% in 2021, then tumbled 163.34% in 2022.
  • A 5-year view of EBT shows it stood at $57.3 million in 2021, then crashed by 163.34% to -$36.3 million in 2022, then rose by 2.36% to -$35.4 million in 2023, then soared by 31.24% to -$24.4 million in 2024, then surged by 79.63% to -$5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$5.0 million in Q4 2025, $2.6 million in Q3 2025, and -$5.5 million in Q2 2025.